Sarepta Therapeutics (SRPT) Profit After Tax (2010 - 2026)

Sarepta Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at $350.9 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 178.4% year-over-year to $350.9 million in Q1 2026; TTM through Mar 2026 was $85.0 million, a 134.2% increase from a year earlier, with the FY2025 full-year figure at -$713.4 million, down 403.27% from the prior year.
• Profit After Tax rose to $350.9 million in Q1 2026 per SRPT's latest filing, from -$412.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at $350.9 million in Q1 2026 and bottomed at -$516.8 million in Q1 2023.
• The 5-year median for Profit After Tax is -$40.9 million (2023), against an average of -$80.2 million.
• Biggest YoY gain for Profit After Tax was 2947.86% in 2025; the steepest drop was 1338.98% in 2025.
• Year by year, Profit After Tax stood at -$106.1 million in 2022, then surged by 143.05% to $45.7 million in 2023, then soared by 248.37% to $159.0 million in 2024, then sank by 359.18% to -$412.2 million in 2025, then jumped by 185.11% to $350.9 million in 2026.
• Per Business Quant, the three latest SRPT Profit After Tax figures stand at $350.9 million (Q1 2026), -$412.2 million (Q4 2025), and -$50.6 million (Q3 2025).